Monopar Therapeutics 将于 8 月 13 日进行 1-5 的反向股票分割。 Monopar Therapeutics to conduct a 1-5 reverse stock split on August 13th.

开发癌症治疗药物的临床阶段生物制药公司Monopar Therapeutics (NASDAQ: MNPR) 将于8月13日进行1-5反向股票分割. Monopar Therapeutics (NASDAQ: MNPR), a clinical-stage biopharmaceutical company developing cancer treatment therapeutics, will undergo a 1-5 reverse stock split on Aug 13th. 该公司的主要候选产品Validive正在进行化学放射治疗引起的口腔粘膜炎的2b/3期临床试验. The firm's lead product candidate, Validive, is in Phase 2b/3 clinical trials for chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients. 此次拆分将在 8 月 12 日收盘后调整股东持股。 The split will adjust shareholder holdings post-Aug 12th close.

文章

Markets Daily

The Enterprise Leader

WKRB 13

-- 显示更少 --

延伸阅读

相关故事